Wedbush Downgrades iTeos Therapeutics (ITOS) to Neutral

Go back to Wedbush Downgrades iTeos Therapeutics (ITOS) to Neutral

iTeos Therapeutics (ITOS) to Wind Down Operations

May 28, 2025 8:32 AM EDT

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing... More